Find out how you can get the best content on Seeking Alpha here. We are short shares of Principia Biopharma (NASDAQ: PRNB), a company whose $2 billion valuation rests on a single obscure molecule ...

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company developing rilzabrutinib, an inhibitor that is in ...

Patient improvement during Phase 2 trial of Principia's drug likely caused not by the drug but by regression to the mean. We believe secondary-endpoint results were likely not statistically ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

SAN FRANCISCO, Oct. 29, 2012 -- SAN FRANCISCO, Oct. 29, 2012 /PRNewswire/ -- Principia Biopharma, Inc., a privately-held biopharmaceutical company focused on advancing best-in-class medicines in ...

March 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant ...

Sanofi has struck a deal to buy its partner Principia Biopharma for $3.7 billion in cash. The takeover will give Sanofi full ownership of a BTK inhibitor it moved into a raft of phase 3 multiple ...

SOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies ...

Guardant Health has announced a strategic collaboration with Principia Biopharma to monitor the response of patients enrolled in clinical trials for Principia's FGFR inhibitor, PRN1371. Principia ...

SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated ...

Principia Biopharma Inc., which is developing drugs to treat cancer and inflammatory diseases, said it secured a $12.5 million second tranche of its Series A financing. It will use the proceeds to ...

Principia Biopharma Inc. said its initial public offering raised about $106 million to fund development of oral therapeutics focused on immunology and oncology. The South San Francisco ...